At-risk non-alcoholic steatohepatitis (NASH) is defined as NASH with NAFLD activity scores (NAS) ≥4 and significant fibrosis (F ≥ 2) diagnosed via histological scoring of liver biopsy.
Recent literature on non-alcoholic fatty liver disease (NAFLD) has sought to characterise its bidirectional association with type 2 diabetes mellitus (T2DM).
Explore ADA’s 2023 updates on diabetes care, focusing on non-alcoholic fatty liver disease (NAFLD) and cirrhosis prevention. Learn from Dr. Kenneth Cusi on risk stratification, diagnostic tools like FIB-4, and latest management recommendations.
Despite ample preclinical evidence of numerous compounds’ efficacy and over 15 years of clinical trials, no pharmacotherapy has yet been approved to treat non-alcoholic steatohepatitis (NASH)
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), has seen a consistent rise in prevalence in recent years owing to the global epidemics of obesity and type 2 diabetes (T2D)
Hepatocytic ballooning is characterised by hepatocyte degeneration identifiable through an enlarged, swollen and rounded cellular phenotype with a distinctly reticulated cytoplasm.
In 2020, a group of international experts proposed that non-alcoholic fatty liver disease (NAFLD) be renamed to metabolic dysfunction-associated fatty liver disease (MAFLD).
Despite an estimated global prevalence of 38%, no pharmacotherapy has yet been approved for non-alcoholic fatty liver disease (NAFLD).
In patients with non-alcoholic steatohepatitis (NASH), the risk of liver-related mortality and decompensation is known to increase proportionally with fibrosis stage. Non-invasive tools, including liver stiffness by vibration-controlled transient elastography (LS-VCTE), have been shown to accurately predict fibrosis stage in NASH patients.
Non-alcoholic fatty liver disease (NAFLD) and congestive heart failure (HF) represent global public health concerns.
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of pathologies ranging from simple steatosis to steatohepatitis (NASH) and fibrosis.
Unveiling the high prevalence of NAFLD and advanced fibrosis in type 2 diabetes patients - a deep-dive into two groundbreaking studies from the US and France. Explore the findings and their implications for future diabetes care.